Our Current Business Focuses on three Major Business Segments:
-Active Pharmaceuticals Ingredients (APIs)
-Advanced Intermediates
-Contract Manufacturing of APIs and Intermediates
(with or without technology transfers)
Active Pharmaceutical Ingredients (APIs):
We focus on niche therapeutic areas of CNS, ARVs, and Controlled substances. We specialize in CNS segments like ADHD, Anti-psychotics, Anti-vertigo, Anti-inflammatory, Pain management, Alzheimer’s disease, and others. We are moving up the value chain by adding the capacities for APIs and other high-growth therapeutic areas like Anti-diabetic, Anti-coagulants, and others.
Advanced Intermediates:
We specialize in the production of advanced intermediates for the narcotic APIs such as Methyl Phenidate, Dexmethylphenidate, Fentanil, Sufentanil, Alfentanil, Methadone, and other controlled substances, Piperazine derivatives, and others. Our intermediates under scale-up and new development will include therapeutic areas like Anti-diabetic, Anti-coagulants, Anti-asthmatic, Anti-parkinson, Alzheimer’s disease, and others.
Contract Manufacturing of APIs and Intermediates (with or without technology transfers):
We are supporting innovators and global generic pharma companies in their increasing need for stringent quality, regulatory compliant and complex chemistry handling facilities. We have many on-going contract manufacturing projects that involve complex chemistry and technological excellence. With the expertise and experience of our technical team we have a proven track record of timely deliverance of the projects.